Ocean Biomedical IncNASDAQ:OCEANASDAQ FSI:E. Delinquent (Issuer missed regulatory filing deadline)
- LAST PRICE0.6900
- TODAY'S CHANGE (%)-0.0236 (-3.3058%)
- Bid / Lots0.6900/ 6
- Ask / Lots0.7300/ 40
- Open / Previous Close0.7200 / 0.7136
- Day Range
- 52 Week Range
- Volume2,610
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OCEA |
|---|---|---|
| 09:32 ET | 725 | 0.72 |
| 09:37 ET | 100 | 0.69001 |
Nov 22, 2024
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q, from 4:45PM ET on Friday Nov 22, 2024 by Dow Jones
4:45PM ET on Friday Nov 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ocean Biomedical Inc | 24.7M | -0.2x | --- |
Enlivex Therapeutics Ltd | 24.4M | -0.9x | --- |
Athira Pharma Inc | 23.8M | -0.2x | --- |
GeoVax Labs Inc | 25.6M | -0.3x | --- |
Lisata Therapeutics Inc | 23.7M | -1.1x | --- |
Citius Pharmaceuticals Inc | 26.0M | -14.1x | --- |
Company Information
Ocean Biomedical, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The Company helps to accelerates the development and commercialization of assets from research universities and medical centers. In oncology, it is engaged in developing a mono-specific and two bi-specific humanized monoclonal antibodies (mAb), product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer (NSCLC), and of glioblastoma multiforme (GBM). It offers three product candidates based on the novel target discoveries: a malaria vaccine candidate targeting either or both of PfSEA-1, and parasite antigen PfGARP, which is referred to as its ODA-570 candidate; a humanized mAb malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-611 candidate, and a small molecule malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-579 candidate.
Contact Information
- Headquarters
- 515 Madison Ave Suite 8078NEW YORK, NY, United States 10022
- Phone
- 646-908-2658
- Fax
- ---
Executives
- Executive Chairman of the Board, Founder
- Chirinjeev Kathuria
- Chief Executive Officer, Director
- Michelle Berrey
- Chief Financial Officer
- Jolie Kahn
- Executive Vice President, Head of External Innovation and Academic Partnerships, Secretary
- Daniel Behr
- Chief Accounting Officer, Assistant Secretary
- Robert Sweeney
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $24.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 34.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.60 |
Book Value | $-2.62 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
